BC Week In Review | Mar 14, 2019
Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
BC Week In Review | Sep 28, 2018
Clinical News

GTx's enobosarm fails Phase II for stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat stress urinary incontinence. Among the 493 postmenopausal women enrolled in the double-blind, U.S. trial, neither of two doses of...
BC Extra | Sep 21, 2018
Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
BioCentury | Aug 10, 2018
Finance

Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential. The importance of this for public health is often overlooked in...
BC Week In Review | Mar 9, 2018
Clinical News

GTx reports additional Phase II stress urinary incontinence data for enobosarm

GTx Inc. (NASDAQ:GTXI) reported data from 18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024). The candidate is a non-steroidal selective androgen receptor modulator (SARM). On the primary...
BC Extra | Mar 5, 2018
Clinical News

GTx rises on stress urinary incontinence data

GTx Inc. (NASDAQ:GTXI) gained $6.44 (38%) to $23.25 on Monday after reporting data from 18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024). The candidate is a non-steroidal...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest an N -carboxyaniline-based selective androgen receptor degrader (SARD) could help treat castration-resistant prostate cancer (CRPC). The SARD is a previously reported N -carboxy-cyanotrifluoromethylaniline analog that binds...
BC Week In Review | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Sept. 26, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $80 million through the sale of 26.8 million shares at $3 in a bumped-up...
BC Extra | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Tuesday, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $72 million through the sale of 24 million shares at $3 in a follow-on and...
BC Week In Review | Jun 23, 2017
Clinical News

GTx reports Phase II data for enobosarm in stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) reported preliminary data from 7 postmenopausal women with stress urinary incontinence in an open-label, U.S. Phase II trial showing that once-daily 3 mg Ostarine enobosarm (GTx-024) reduced the mean number of stress...
Items per page:
1 - 10 of 319
BC Week In Review | Mar 14, 2019
Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
BC Week In Review | Sep 28, 2018
Clinical News

GTx's enobosarm fails Phase II for stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat stress urinary incontinence. Among the 493 postmenopausal women enrolled in the double-blind, U.S. trial, neither of two doses of...
BC Extra | Sep 21, 2018
Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
BioCentury | Aug 10, 2018
Finance

Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential. The importance of this for public health is often overlooked in...
BC Week In Review | Mar 9, 2018
Clinical News

GTx reports additional Phase II stress urinary incontinence data for enobosarm

GTx Inc. (NASDAQ:GTXI) reported data from 18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024). The candidate is a non-steroidal selective androgen receptor modulator (SARM). On the primary...
BC Extra | Mar 5, 2018
Clinical News

GTx rises on stress urinary incontinence data

GTx Inc. (NASDAQ:GTXI) gained $6.44 (38%) to $23.25 on Monday after reporting data from 18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024). The candidate is a non-steroidal...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest an N -carboxyaniline-based selective androgen receptor degrader (SARD) could help treat castration-resistant prostate cancer (CRPC). The SARD is a previously reported N -carboxy-cyanotrifluoromethylaniline analog that binds...
BC Week In Review | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Sept. 26, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $80 million through the sale of 26.8 million shares at $3 in a bumped-up...
BC Extra | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Tuesday, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $72 million through the sale of 24 million shares at $3 in a follow-on and...
BC Week In Review | Jun 23, 2017
Clinical News

GTx reports Phase II data for enobosarm in stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) reported preliminary data from 7 postmenopausal women with stress urinary incontinence in an open-label, U.S. Phase II trial showing that once-daily 3 mg Ostarine enobosarm (GTx-024) reduced the mean number of stress...
Items per page:
1 - 10 of 319